自身免疫性脑炎的临床电标记物

Ty - jour

T1 -自身免疫性脑炎的电临床生物标志物

AU - Wesselingh，罗柏

AU -布罗德利，詹姆斯

AU -秃鹰，凯瑟琳

AU -塔林顿，大卫

AU -塞内维拉特纳，乌达亚

AU - Kyndt，克里斯

AU -斯坦科维奇，吉姆

AU - Paul Sanfilippo

AU -内斯比特，凯西

AU - D'Souza，温德尔

AU -麦克多内尔，理查德

AU - Butzkueven, Helmut

AU - O'Brien, Terence J。

AU - Monif, Mastura

N1 -资助信息:A/ Wendyl D’souza教授的工资由墨尔本大学部分资助。他曾获得UCB Pharma Australia & Global的旅行、研究人员发起、科学顾问委员会和演讲者荣誉奖;研究人员发起的科学顾问委员会，卫材澳大利亚和全球的旅行和演讲荣誉;来自Liva Nova的顾问委员会酬金;诺华制药、辉瑞制药和赛诺菲- synthelabo提供的教育资助;教育;来自澳大利亚葛兰素史克神经病学的旅行和奖学金，以及来自SciGen制药公司的酬金。资助信息:我们要感谢Callum Hollis, Ramja Kokulan, Patrick Carney, Annie Roten和John Archer在脑电图数据的采购和审查方面的协助，以及澳大利亚自身免疫性脑炎联盟对项目的支持。A/ Wendyl D’souza教授?他的薪水部分由墨尔本大学资助。 He has received travel, investigator-initiated, scientific advisory board and speaker honoraria from UCB Pharma Australia & Global; investigator-initiated, scientific advisory board, travel and speaker honoraria from Eisai Australia & Global; advisory board honoraria from Liva Nova; educational grants from Novartis Pharmaceuticals, Pfizer Pharmaceuticals and Sanofi-Synthelabo; educational; travel and fellowship grants from GSK Neurology Australia, and honoraria from SciGen Pharmaceuticals. Dr Katherine Buzzard has received support to attend educational events from Sanofi Genzyme, Teva, Biogen, Merck, Roche and Novartis, has received honorarium for presentations from Teva, Sanofi Genzyme and Biogen, and has served on the Advisory Board for Merck. Prof Richard Macdonell reports no disclosures. Prof Helmut Butzkueven's research is funded by an Australian National Health Medical Research Council Investigator Grant. His institution receives funding from Biogen, Roche, Merck, Alexion and Novartis for speaker engagements, study steering and advisory committee service. He is on the editorial board of Multiple Sclerosis and Related Disorders and the Steering committee of the Brain Health Initiative (Oxford Health Policy Forum). Prof Terence J. O'Brien receives research funding from Biogen, UCB Pharma, Eisai Pharma, Anavex Pharmaceuticals, Zynerba Pharmaceuticals, and serves on the scientific advisory boards for UCB Pharma, Eisai Pharmaceuticals, Zynerba Pharmaceuticals, ES Therapeutics, Seqirus Pharmaceuticals. Dr Mastura Monif? has served on advisory board for Merck, and has received speaker honoraria from Merck and Biogen. Her institution receives funding from Merck, Australian National Health Medical Research Council, Brain Foundation, Charles and Sylvia Viertel Foundation, Bethlehem and Griffith Foundation and MS Research Australia. The remaining authors report no conflicts of interest. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. Funding Information: Dr Mastura Monif’ has served on advisory board for Merck, and has received speaker honoraria from Merck and Biogen. Her institution receives funding from Merck, Australian National Health Medical Research Council, Brain Foundation, Charles and Sylvia Viertel Foundation, Bethlehem and Griffith Foundation and MS Research Australia. Funding Information: Prof Helmut Butzkueven’s research is funded by an Australian National Health Medical Research Council Investigator Grant. His institution receives funding from Biogen, Roche, Merck, Alexion and Novartis for speaker engagements, study steering and advisory committee service. He is on the editorial board of Multiple Sclerosis and Related Disorders and the Steering committee of the Brain Health Initiative (Oxford Health Policy Forum). Publisher Copyright: © 2022 Elsevier Inc.

Py - 2022/3

Y1 - 2022/3

目的:评价脑电图(EEG)变化作为急性自身免疫性脑炎(AIE)诊断和预后生物标志物的应用。方法:回顾性分析7家医院131例AIE患者。在入院期间和12个月时收集临床数据。脑电图采用标准报告形式进行复查。脑电图生物标记物、AIE亚型和临床结果之间的关系采用逻辑回归模型进行评估。结果:存在叠加快速活性(OR 34.33;95% ci 3.90, 4527.27;p < 0.001)，波动脑电图异常(OR 6.60;95% ci 1.60, 37.59;p = 0.008)和半球病灶(OR 28.48; 95% CI 3.14, 3773.14; p < 0.001) were significantly more common in N-methyl-D-aspartate receptor (NMDAR) antibody-associated patients with AIE compared to other AIE subtypes. Abnormal background rhythm was associated with a poor mRS (modified Rankin score) at discharge (OR 0.29; 95% CI 0.10, 0.75; p = 0.01) and improvement in mRS at 12 months compared with admission mRS (3.72; 95% CI 1.14, 15.23; p = 0.04). Significance: We have identified EEG biomarkers that differentiate NMDAR AIE from other subtypes. We have also demonstrated EEG biomarkers that are associated with poor functional outcomes.

目的:评价脑电图(EEG)变化作为急性自身免疫性脑炎(AIE)诊断和预后生物标志物的应用。方法:回顾性分析7家医院131例AIE患者。在入院期间和12个月时收集临床数据。脑电图采用标准报告形式进行复查。脑电图生物标记物、AIE亚型和临床结果之间的关系采用逻辑回归模型进行评估。结果:存在叠加快速活性(OR 34.33;95% ci 3.90, 4527.27;p < 0.001)，波动脑电图异常(OR 6.60;95% ci 1.60, 37.59;p = 0.008)和半球病灶(OR 28.48; 95% CI 3.14, 3773.14; p < 0.001) were significantly more common in N-methyl-D-aspartate receptor (NMDAR) antibody-associated patients with AIE compared to other AIE subtypes. Abnormal background rhythm was associated with a poor mRS (modified Rankin score) at discharge (OR 0.29; 95% CI 0.10, 0.75; p = 0.01) and improvement in mRS at 12 months compared with admission mRS (3.72; 95% CI 1.14, 15.23; p = 0.04). Significance: We have identified EEG biomarkers that differentiate NMDAR AIE from other subtypes. We have also demonstrated EEG biomarkers that are associated with poor functional outcomes.

自身免疫性脑炎

KW -生物标记

Kw -脑电

Kw - lgi-1

Kw - nmda

UR - http://www.scopus.com/inward/record.url?scp=85123595205&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2022.108571

DO - 10.1016/j.yebeh.2022.108571

M3 -物品

C2 - 35101840

安- scopus:85123595205

Vl - 128

JO -癫痫和行为

癫痫和行为

Sn - 1525-5050

M1 - 108571

呃- - - - - -